Biotechnology
Antengene Announces XPOVIO® (selinexor) Approved for Its Third Indication in South Korea, Bringing Fresh Hope to Patients with MM in the Country
* This approval for XPOVIO® for the treatment of patients with multiple myeloma (MM) marks the third approved indication of the drug inSouth Korea. * To date, XPOVIO® has already been included in national health insurance or reimbursement schemes inSouth Korea, the mainland of China, Australia...
2024-10-18 10:35
2200
OmniaBio Announces Opening of New Commercial Manufacturing Facility in Canada, Bringing Life-Saving Cell and Gene Therapies to Patients
The site will add state-of-the-art CGT capacity and employ artificial intelligence and automation to achieve critical product supply efficiencies for North American and global biotherapy clients HAMILTON, ON, Oct. 18, 2024 /PRNewswire/ -- Today OmniaBio Inc. will announce the opening of a new No...
2024-10-18 07:00
1512
Exclusive Interview with Lang Guojun, founder of Sanyou Bio: The Key to Breaking the Bottleneck of New Drug Innovation--The Past and Future of the Super-Trillion Molecule Library
SHANGHAI, Oct. 17, 2024 /PRNewswire/ -- In the ninth year since the establishment of Sanyou Bio, Lang Guojun believes that the time is perfect to unveil the world's largest super-trillion molecule library. During the interview with Tongxieyi, he frankly and confidently expressed, "Nine years of ...
2024-10-17 22:00
1214
Chipscreen Biosciences' Innovative Anti-Tumor Drug CS231295 Tablets: Investigational New Drug (IND) Application Accepted
SHENZHEN, China, Oct. 17, 2024 /PRNewswire/ -- On October 17, 2024, Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen Biosciences, Stock Symbol: 688321.SH) submitted the company's Investigational New Drug (IND) application for CS231295 tablets, a Class 1 innovative drug for the treatment of t...
2024-10-17 21:38
1661
Amplo Biotechnology Announces Three Presentations at the European Society of Gene and Cell Therapy 31st Annual Congress
SAN DIEGO, Oct. 17, 2024 /PRNewswire/ -- Amplo Biotechnology, a biotechnology company developing genetic medicines for the treatment of neuromuscular diseases, announced the presentation of three posters at the European Society of Gene and Cell Therapy (ESGCT) 31st Annual Congress, taking place f...
2024-10-17 18:39
1001
Telix Q3 2024 Business Update - Quarterly Revenue Exceeds AU$200M
MELBOURNE, Australia, Oct. 17, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update on its revenue and operational performance for the quarter ended30 September 2024 (Q3 2024). Revenue update, full year guidance reaffirmed * Unaudited to...
2024-10-17 15:54
1635
KIND Announces Late-Breaking Abstract Accepted for Presentation on AND017 Clinical Trials to Treat Anemia in Chronic Kidney Disease (CKD) at ASN - Kidney Week 2024
SAN FRANCISCO, Oct. 17, 2024 /PRNewswire/ -- Kind Pharmaceutical ("Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC"), a clinical-stage biopharmaceutical company focused on developing innovative medicines to treat hematological diseases and cancers, today announced that the late-br...
2024-10-17 15:44
1111
Cambrex Opens New Stability Storage Facility in Durham, North Carolina
EAST RUTHERFORD, N.J., Oct. 17, 2024 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced that their stability storage business, Q1 Scientific, has opened a new cGMP facility inDurham, North Carolina, expanding its capacity for envi...
2024-10-17 15:00
1471
Bio X Cell Announces Board of Director Appointments
A Leading Producer of Monoclonal Antibodies LEBANON, N.H., Oct. 17, 2024 /PRNewswire/ -- Bio X Cell, LLC ("BXC" or the "Company"), the world's leading producer of monoclonal antibodies for pre-clinicalin vivo research applications, is pleased to announce the appointments ofAlan Hirzel and Kevin ...
2024-10-17 14:00
1270
IND Application for a Phase Ⅲ Clinical Study of KN026 Combined with Albumin-bound Docetaxel as Neoadjuvant Treatment for Breast Cancer was Approved
SUZHOU, China, Oct. 17, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966 HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (stock code: 1093.HK) jointly announced that an application for a phase III clinical study (Study ID: KN026-004) of the anti-HER2 bispecific antibody KN026 combine...
2024-10-17 10:15
1772
Innovent Announces Phase 2 Clinical Study of Picankibart (IBI112) in Chinese Patients with Ulcerative Colitis Met Primary Endpoint
SAN FRANCISCO and SUZHOU, China, Oct. 17, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabo...
2024-10-17 08:00
3552
Presagen's AI fertility product Life Whisperer acquired by Astec
ADELAIDE, Australia, Oct. 17, 2024 /PRNewswire/ -- Astec, a global manufacturer of medical equipment for assisted reproduction, has acquired Presagen's fertility product Life Whisperer, a non-invasive and rapid embryo and egg (oocyte) assessment tool designed to improve pregnancy outcomes for IVF...
2024-10-17 03:11
1695
WuXi Biologics Receives ESG Corporate Platinum Award from The Asset for Fourth Consecutive Year
HONG KONG, Oct. 16, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has received a Platinum Award from The Asset ESG (Environmental, Social and Governance) Corporate Awards ...
2024-10-16 20:00
3162
IGCS Late Breaking Abstract and The Lancet: Akeso Published Positive PFS and OS Results from Phase 3 First-Line Study of Cadonilimab in Cervical Cancer
HONG KONG, Oct. 16, 2024 /PRNewswire/ -- Akeso Biopharma (9926.HK) (" Akeso", the "Company" ) announced positive results in progression-free survival (PFS) and overall survival (OS) from its Phase 3 clinical study (COMPASSION-16/AK104-303). This study evaluated the efficacy of its independently...
2024-10-16 19:02
1264
TenNor Announces More than 300 Million RMB Financing to Support Development and Commercialization of Late-Stage Assets Including Rifasutenizol for Heliobacter pylori Infections
SUZHOU, China, Oct. 16, 2024 /PRNewswire/ -- TenNor Therapeutics, a clinical stage company dedicated to developing new therapies to address unmet needs in infectious diseases, announced today the initial closing of a Series E financing round for more than300 million RMB. New investor AMR Action F...
2024-10-16 18:00
1654
Join the GenScript Biotech Global Forum: Unlocking Innovations in Cell and Gene Therapies
PISCATAWAY, N.J., Oct. 16, 2024 /PRNewswire/ -- The global cell and gene therapy (CGT) industry is poised for remarkable growth, driven by significant advances in life sciences and robust investments from capital markets. To strengthen this vital sector, GenScript is bringing together leading sc...
2024-10-16 17:43
1024
Exyte completes acquisition of Kinetics
* Closing of transaction following the approval by all required regulatory bodies * Acquisition of industry leader in installation services, equipment, and technical facility management * The company serves high-tech industries such as semiconductor, biopharma, and batteries * Further st...
2024-10-16 17:00
1474
Frost & Sullivan grants the 2024 Global Pluripotent stem cell drug R&D Innovation Award to ZEPHYRM BIOTECHNOLOGIES
SHANGHAI, Oct. 16, 2024 /PRNewswire/ -- The 18th The Growth Innovation Leadership (GIL) Council & the 3rd New Investment Conference in 2024 was held in Shanghai from August 28 to 30, 2024. On the evening of August 28, the prestigious 2024 Global and China Awards for Growth, Innovation, and Leaders...
2024-10-16 13:35
1440
PharmAust affirms corporate strategy with name change to Neurizon Therapeutics
MELBOURNE, Australia, Oct. 15, 2024 /PRNewswire/ -- Neurizon Therapeutics Limited (ASX: NUZ) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing treatments for neurodegenerative diseases, is pleased to announce it has officially changed its name from PharmAust L...
2024-10-16 04:14
1317
Chiglitazar for the Treatment of MASH Phase II Clinical Study Selected for Oral Presentation at the 2024 American Liver Disease Annual Meeting
SHENZHEN, China, Oct. 15, 2024 /PRNewswire/ -- On October 15, 2024, the list of selected candidates for the oral report of the American Association for the Study of the Liver (AASLD 2024) annual meeting was officially announced online. The abstract of the Phase II clinical study (CGZ203 trial) on...
2024-10-15 22:08
1381
Week's Top Stories
Most Reposted
Mayapada Hospitality Holding Open the first voco Hotel in Indonesia.
[Picked up by 309 media titles]
2024-12-20 16:25
AI and Cyber Security Dominate ASEAN Enterprises' Digital Transformation Priorities
[Picked up by 306 media titles]
2024-12-20 18:11
XTransfer and OCBC Jointly Announce Comprehensive Partnership
[Picked up by 266 media titles]
2024-12-23 17:36
CKGSB Successfully Hosts 2024 MBA Professor Training Program for Western China
[Picked up by 252 media titles]
2024-12-24 00:06ebm-papst A&NZ Achieves Complete Operational Carbon Neutrality in appropriate Scope 1,2 and 3 criterion in 2023
[Picked up by 244 media titles]
2024-12-25 15:45Most Read
AI and Cyber Security Dominate ASEAN Enterprises' Digital Transformation Priorities
2024-12-20 18:11
12177
Mayapada Hospitality Holding Open the first voco Hotel in Indonesia.
2024-12-20 16:25
7143